documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
40 rows where docket_id = "FDA-2025-P-4282" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, open_for_comment, posted_date (date), comment_start_date (date), last_modified (date)
document_type 2
agency_id 1
- FDA 40
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2025-P-4282-0172 | FDA | None FDA-2025-P-4282 | Reference 27 - Large - Violence in first-episode psychosis A systematic review and meta-analysis | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:10Z | 0 | 0 | 09000064b91d3d7f | |||
| FDA-2025-P-4282-0154 | FDA | None FDA-2025-P-4282 | Reference 9 - Chalasani - Clozapine Impact on Clinical Outcomes and Aggression in Severely Ill Adolescents with Childhood-Onset Schizophrenia | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:18Z | 0 | 0 | 09000064b91d3d6d | |||
| FDA-2025-P-4282-0160 | FDA | None FDA-2025-P-4282 | Reference 15 - di Giacomo et al - Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:36Z | 0 | 0 | 09000064b91d3d73 | |||
| FDA-2025-P-4282-0164 | FDA | None FDA-2025-P-4282 | Reference 19 - Fazel et al - Schizophrenia and Violence Systematic Review and Meta-Analysis | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:49Z | 0 | 0 | 09000064b91d3d77 | |||
| FDA-2025-P-4282-0167 | FDA | None FDA-2025-P-4282 | Reference 22 - Galletly - Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:57Z | 0 | 0 | 09000064b91d3d7a | |||
| FDA-2025-P-4282-0148 | FDA | None FDA-2025-P-4282 | Reference 4 - Bitter - Effectiveness of Clozapine Olanzapine Quetiapine Risperidone and Haloperidol Monotherapy | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:42:58Z | 0 | 0 | 09000064b91d0f90 | |||
| FDA-2025-P-4282-0151 | FDA | None FDA-2025-P-4282 | Reference 7 - Cavaliere - Anti-Aggressive Effects of Clozapine in Involuntarily Committed Black Patients with Severe Mental Illness | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:09Z | 0 | 0 | 09000064b91d0f93 | |||
| FDA-2025-P-4282-0178 | FDA | None FDA-2025-P-4282 | Reference 33 - Sariaslan - Associations between individual antipsychotics and the Risk of Arrests and Convictions of Violent and Other Crime | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:30Z | 0 | 0 | 09000064b91d3d85 | |||
| FDA-2025-P-4282-0150 | FDA | None FDA-2025-P-4282 | Reference 6 - Buckley - Violence and Schizophrenia Clozapine as a Specific Antiaggressive Agent | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:05Z | 0 | 0 | 09000064b91d0f92 | |||
| FDA-2025-P-4282-0156 | FDA | None FDA-2025-P-4282 | Reference 11 - Citrome - Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:24Z | 0 | 0 | 09000064b91d3d6f | |||
| FDA-2025-P-4282-0158 | FDA | None FDA-2025-P-4282 | Reference 13 - de Domenico - The effect of clozapine of aggressive behaviour in patients with chronic schizophrenia | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:30Z | 0 | 0 | 09000064b91d3d71 | |||
| FDA-2025-P-4282-0169 | FDA | None FDA-2025-P-4282 | Reference 24 - Herman - Clinical Response to Clozapine Treatment of 11 Chronic Patients in a State Psychiatric Hospital | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:02Z | 0 | 0 | 09000064b91d3d7c | |||
| FDA-2025-P-4282-0155 | FDA | None FDA-2025-P-4282 | Reference 10 - Chiles - Effects of Clozapine on Use of Seclusion and Restraint at a State Hospital | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:21Z | 0 | 0 | 09000064b91d3d6e | |||
| FDA-2025-P-4282-0159 | FDA | None FDA-2025-P-4282 | Reference 14 - Dennis - Clozapine Therapy in a State Hospital | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:33Z | 0 | 0 | 09000064b91d3d72 | |||
| FDA-2025-P-4282-0163 | FDA | None FDA-2025-P-4282 | Reference 18 - Fazel Grann - The Population Impact of Severe Mental Illness on Violent Crime | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:46Z | 0 | 0 | 09000064b91d3d76 | |||
| FDA-2025-P-4282-0168 | FDA | None FDA-2025-P-4282 | Reference 23 - Gammon - Clozapine Why Is It So Uniquely Effective in the Treatment ofa Range of Neuropsychiatric Disorders | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:00Z | 0 | 0 | 09000064b91d3d7b | |||
| FDA-2025-P-4282-0182 | FDA | None FDA-2025-P-4282 | Reference 37 - Wagner et al - Clozapine Optimization A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:42Z | 0 | 0 | 09000064b91d3d89 | |||
| FDA-2025-P-4282-0152 | FDA | None FDA-2025-P-4282 | Reference 8 - Clozapine Impact on Clinical Outcomes and Aggression in Severly Ill Adolescents with Childhood-Onset Schizophrenia | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:12Z | 0 | 0 | 09000064b91d3d6b | |||
| FDA-2025-P-4282-0171 | FDA | None FDA-2025-P-4282 | Reference 26 - Kranzler - Clozapine Its Impact on Aggressive Behavior Among Children and Adolescents with Schizophrenia | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:08Z | 0 | 0 | 09000064b91d3d7e | |||
| FDA-2025-P-4282-0173 | FDA | None FDA-2025-P-4282 | Reference 28 - Newman - Management of Aggression | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:13Z | 0 | 0 | 09000064b91d3d80 | |||
| FDA-2025-P-4282-0175 | FDA | None FDA-2025-P-4282 | Reference 30 - Potkin - Predicting Suicidal Risk in Schizophrenic and Schizoaffective Patients in a Prospective Two-Year Trial | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:19Z | 0 | 0 | 09000064b91d3d82 | |||
| FDA-2025-P-4282-0179 | FDA | None FDA-2025-P-4282 | Reference 34 - Shaheen - The Effect of Clozapine on Violence - Aggression in Adults with Mental Illness and Personality Disorders | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:33Z | 0 | 0 | 09000064b91d3d86 | |||
| FDA-2025-P-4282-0181 | FDA | None FDA-2025-P-4282 | Reference 36 - Volavka - Efficacy of Clozapine Olanzapine Risperidone and Haloperidol in Schizophrenia and Schizoaffective Disorder | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:39Z | 0 | 0 | 09000064b91d3d88 | |||
| FDA-2025-P-4282-0146 | FDA | None FDA-2025-P-4282 | Reference 2 - Barnes - Evidence-based Guidelines for the Pharmacological Treatment of Schizophrenia | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:42:51Z | 0 | 0 | 09000064b91d0f8e | |||
| FDA-2025-P-4282-0176 | FDA | None FDA-2025-P-4282 | Reference 31 - Rabinowitz - Effect of clozapine on physical and verbal aggression | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:23Z | 0 | 0 | 09000064b91d3d83 | |||
| FDA-2025-P-4282-0166 | FDA | None FDA-2025-P-4282 | Reference 21 - Frogley - A systematic review of the evidence of clozapines anti-aggressive effects | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:54Z | 0 | 0 | 09000064b91d3d79 | |||
| FDA-2025-P-4282-0180 | FDA | None FDA-2025-P-4282 | Reference 35 - Volavka - Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:36Z | 0 | 0 | 09000064b91d3d87 | |||
| FDA-2025-P-4282-0177 | FDA | None FDA-2025-P-4282 | Reference 32 - Reid - Internet Archive Interlibrary Loan Fulfillment | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:27Z | 0 | 0 | 09000064b91d3d84 | |||
| FDA-2025-P-4282-0149 | FDA | None FDA-2025-P-4282 | Reference 5 - Buchanan - The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:01Z | 0 | 0 | 09000064b91d0f91 | |||
| FDA-2025-P-4282-0153 | FDA | None FDA-2025-P-4282 | Reference 8a - Chengappa - Clozapine Its impact on Aggressive Behavior Among Patients in a State Psychiatric Hospital | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:15Z | 0 | 0 | 09000064b91d3d6c | |||
| FDA-2025-P-4282-0157 | FDA | None FDA-2025-P-4282 | Reference 12 - Citrome - Effects of Clozapine Olanzapine Risperidone and Haloperidol on Hostility Among Patients with Schizophrenia | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:27Z | 0 | 0 | 09000064b91d3d70 | |||
| FDA-2025-P-4282-0161 | FDA | None FDA-2025-P-4282 | Reference 16 - Ebrahim - Patient Response to Clozapine in a Forensic Psychiatric Hospital | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:41Z | 0 | 0 | 09000064b91d3d74 | |||
| FDA-2025-P-4282-0165 | FDA | None FDA-2025-P-4282 | Reference 20 - Fazel et al - Violent crime suicide and premature mortality in patients with schizophrenia and related disorders | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:51Z | 0 | 0 | 09000064b91d3d78 | |||
| FDA-2025-P-4282-0170 | FDA | None FDA-2025-P-4282 | Reference 25 - Keepers - The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:05Z | 0 | 0 | 09000064b91d3d7d | |||
| FDA-2025-P-4282-0174 | FDA | None FDA-2025-P-4282 | Reference 29 - Nolan - Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and Schizoaffective Disorder | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:44:16Z | 0 | 0 | 09000064b91d3d81 | |||
| FDA-2025-P-4282-0145 | FDA | None FDA-2025-P-4282 | Reference 1 - Balbuena - Does Clozapine Promote Employability and Reduce Offending Among Mentally Disordered Offenders | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:42:48Z | 0 | 0 | 09000064b91d0f8d | |||
| FDA-2025-P-4282-0147 | FDA | None FDA-2025-P-4282 | Reference 3 - Bhavsar - Clozapine Treatment and Offending A Within-Subject Study of Patients With Psychotic Disorders in Sweden | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:42:54Z | 0 | 0 | 09000064b91d0f8f | |||
| FDA-2025-P-4282-0162 | FDA | None FDA-2025-P-4282 | Reference 17 - Faden - A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder | Supporting & Related Material | Background Material | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-25T02:43:43Z | 0 | 0 | 09000064b91d3d75 | |||
| FDA-2025-P-4282-0001 | FDA | None FDA-2025-P-4282 | Citizen Petition from Gilbert Honigfeld | Other | Citizen Petition | 2025-09-25T04:00:00Z | 2025 | 9 | 2025-09-25T04:00:00Z | 2026-01-10T13:14:10Z | 1 | 0 | 09000064b8fdcd91 | ||
| FDA-2025-P-4282-0002 | FDA | None FDA-2025-P-4282 | Acknowledgement Letter from FDA DMB to Gilbert Honigfeld | Other | Acknowledgement Letter/Receipt | 2025-09-25T04:00:00Z | 2025 | 9 | 2025-09-25T04:00:00Z | 2025-09-25T19:20:21Z | 0 | 0 | 09000064b8fdcda7 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;